CYP450 Pharmacogenetic treatment strategies for antipsychotics: A review of the evidence

Schizophrenia Research

Volumn 149, Issue 1-3, 2013, Pages 1-14

  Ravyn, Dana ^a   Ravyn, Vipa ^b   Lowney, Robert ^a   Nasrallah, Henry A ^c  

^a CMEology   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Antipsychotic; Cytochrome; Metabolism; Pharmacogenetics; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FLUPHENAZINE; HALOPERIDOL; ILOPERIDONE; LOXAPINE; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL;

AFRICAN AMERICAN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; AREA UNDER THE CURVE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CAUCASIAN; COHORT ANALYSIS; CYP450 GENE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LABELING; DRUG METABOLISM; DRUG USE; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYNDROME; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GENOTYPING TECHNIQUE; HUMAN; NEGRO; NEUROLOGIC DISEASE; PARKINSONISM; PHARMACOGENETICS; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT PROLONGATION; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC; CYTOCHROME; METABOLISM; PHARMACOGENETICS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; PHARMACOGENETICS; SCHIZOPHRENIA;

EID: 84881249354     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.06.035     Document Type: Review

References (170)

1. Aitchison K.J., Munro J., Wright P., Smith S., Makoff A.J., Sachse C., Sham P.C., Murray R.M., Collier D.A., Kerwin R.W. Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation. Br. J. Clin. Pharmacol. 1999, 48(3):388-394.
2. Alenius M., Wadelius M., Dahl M.L., Hartvig P., Lindstrom L., Hammarlund-Udenaes M. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J. Psychiatr. Res. 2008, 42(11):884-893.
3. Allen M.H., Feifel D., Lesem M.D., Zimbroff D.L., Ross R., Munzar P., Spyker D.A., Cassella J.V. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2011, 72(10):1313-1321.
4. Altman R.B. PharmGKB: a logical home for knowledge relating genotype to drug response phenotype. Nat. Genet. 2007, 39(4):426.
5. Altman R.B. Pharmacogenomics: "noninferiority" is sufficient for initial implementation. Clin. Pharmacol. Ther. 2011, 89(3):348-350.
6. Amirimani B., Ning B., Deitz A.C., Weber B.L., Kadlubar F.F., Rebbeck T.R. Increased transcriptional activity of the CYP3A4*2003, 42(4):299-305.
7. Andreassen O.A., MacEwan T., Gulbrandsen A.K., McCreadie R.G., Steen V.M. Non-functional CYP2D6*2):174-179.
8. Aripiprazole package insert, 2012. Princeton, NJ: Bristol-Myers Squibb Company.
9. Armstrong M., Daly A.K., Blennerhassett R., Ferrier N., Idle J.R. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6*23-26.
10. Arranz M.J., Dawson E., Shaikh S., Sham P., Sharma T., Aitchison K., Crocq M.A., Gill M., Kerwin R., Collier D.A. Cytochrome P4502D6 genotype does not determine response to clozapine. Br. J. Clin. Pharmacol. 1995, 39(4):417-420.
11. Arranz M.J., Rivera M., Munro J.C. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 2011, 25(11):933-969.
12. Arthur H., Dahl M.L., Siwers B., Sjoqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J. Clin. Psychopharmacol. 1995, 15(3):211-216.
13. Bakken G.V., Rudberg I., Christensen H., Molden E., Refsum H., Hermann M. Metabolism of quetiapine by CYP3A4 and CYP3A5*37(2):254-258.
14. Basile V.S., Ozdemir V., Masellis M., Walker M.L., Meltzer H.Y., Lieberman J.A., Potkin S.G., Alva G., Kalow W., Macciardi F.M., Kennedy J.L. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol. Psychiatry 2000, 5(4):410-417.
15. Beedham C., Miceli J.J., Obach R.S. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J. Clin. Psychopharmacol. 2003, 23(3):229-232.
16. Berecz R, de la Rubia A, Dorado P, Fernández-Salguero P, Dahl ML, LLerena A. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6*2C9 genotype. Eur. J. Clin. Pharmacol. 2003, 59(1):45-50.
17. Bertilsson L., Dahl M.L., Dalen P., Al-Shurbaji A. Molecular genetics of CYP2D6*2002, 53(2):111-122.
18. Bigos L., Bies R.R., Pollack B.G., Lowy J.J., Zhang F., Weinberger D.R. Genetic variation in CYP3A4*2011, 16(6):620-625.
19. Bork J.A., Rogers T., Wedlund P.J., de Leon J. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J. Clin. Psychiatry 1999, 60(7):469-476.
20. Brockmoller J., Kirchheiner J., Schmider J., Walter S., Sachse C., Muller-Oerlinghausen B., Roots I. The impact of the CYP2D6*2002, 72(4):438-452.
21. Brosen K. Pharmacogenetic and Pharmacogenomics. 2004 International Union of Basic and Clinical Pharmacology, Irvine, CA 2004, (Chapter 4).
22. Cascorbi I. Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. Eur. J. Clin. Investig. 2003, 33(Suppl. 2):17-22.
23. Cha D.S., McIntyre R.S. Treatment-emergent adverse events associated with atypical antipsychotics. Expert. Opin. Pharmacother. 2012, 13(11):1587-1598.
24. Chong S.A. Tardive dyskinesia in CYP2D6 polymorphism in Chinese. Br. J. Psychiatry 1997, 171:586.
25. Clozapine package insert, 2010. East Hanover, NJ: Novartis Pharmaceuticals Corporation.
26. Cooper T.B., Kelly R.G. GLC analysis of loxapine, amoxapine, and their metabolites in serum and urine. J. Pharm. Sci. 1979, 68(2):216-219.
27. Crews K.R., Hicks J.K., Pui C.H., Relling M.V., Evans W.E. Pharmacogenomics and individualized medicine: translating science into practice. Clin. Pharmacol. Ther. 2012, 92(4):467-475.
28. Dahl M.L., Ekqvist B., Widen J., Bertilsson L. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr. Scand. 1991, 84(1):99-102.
29. Dahl M.L., Llerena A., Bondesson U., Lindstrom L., Bertilsson L. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br. J. Clin. Pharmacol. 1994, 37(1):71-74.
30. Dahl-Puustinen M.L., Liden A., Alm C., Nordin C., Bertilsson L. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin. Pharmacol. Ther. 1989, 46(1):78-81.
31. de Leon J., Susce M.T., Pan R.M., Fairchild M., Koch W.H., Wedlund P.J. The CYP2D6*2005, 66(1):15-27.
32. de Leon J., Susce M.T., Pan R.M., Koch W.H., Wedlund P.J. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6*2005, 25(5):448-456.
33. de Leon J., Susce M.T., Murray-Carmichael E. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool. Mol. Diagn. Ther. 2006, 10(3):135-151.
34. de Leon J., Sandson N.B., Cozza K.L. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part II. Psychosomatics 2008, 49(4):347-361.
35. Desai M., Tanus-Santos J.E., Li L., Gorski J.C., Arefayene M., Liu Y., Desta Z., Flockhart D.A. Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6*105-113.
36. Dettling M., Sachse C., Brockmoller J., Schley J., Muller-Oerlinghausen B., Pickersgill I., Rolfs A., Schaub R.T., Schmider J. Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology (Berl) 2000, 152(1):80-86.
37. Dettling M., Sachse C., Muller-Oerlinghausen B., Roots I., Brockmoller J., Rolfs A., Cascorbi I. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. Pharmacopsychiatry 2000, 33(6):218-220.
38. Dorado P, Peñas-LLedó E.M, de la Rubia A, LLerena A. Relevance of CYP2D6*10(7):1083-1089.
39. Eap C.B., Guentert T.W., Schaublin-Loidl M., Stabl M., Koeb L., Powell K., Baumann P. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin. Pharmacol. Ther. 1996, 59(3):322-331.
40. Eiermann B., Engel G., Johansson I., Zanger U.M., Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br. J. Clin. Pharmacol. 1997, 44(5):439-446.
41. Elens L., Bouamar R., Hesselink D.A., Haufroid V., van Gelder T., van Schaik R.H. The new CYP3A4*2012, 22(5):373-380.
42. Ellingrod V.L., Miller D., Schultz S.K., Wehring H., Arndt S. CYP2D6*2002, 12(1):55-58.
43. Ellingrod V.L., Schultz S.K., Arndt S. Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6. Pharmacotherapy 2002, 22(11):1416-1419.
44. Fang J., McKay G., Song J., Remillrd A., Li X., Midha K. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab. Dispos. 2001, 29(12):1638-1643.
45. Fleeman N., Dundar Y., Dickson R., Jorgensen A., Pushpakom S., McLeod C., Pirmohamed M., Walley T. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J. 2011, 11(1):1-14.
46. Fraguas D., Kirchoff D. Pharmacogenetics of antipsychotic-induced weight gain. Med. Sci. Monit. 2006, 12(5):LE6-LE7.
47. Frueh F.W., Amur S., Mummaneni P., Epstein R.S., Aubert R.E., DeLuca T.M., Verbrugge R.R., Burckart G.J., Lesko L.J. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy 2008, 28(8):992-998.
48. Fu Y., Fan C.H., Deng H.H., Hu S.H., Lv D.P., Li L.H., Wang J.J., Lu X.Q. Association of CYP2D6*2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol. Sin. 2006, 27(3):328-332.
49. Gaedigk A., Bradford L.D., Marcucci K.A., Leeder J.S. Unique CYP2D6*2002, 72(1):76-89.
50. Glazer W.M. Does loxapine have "atypical" properties? Clinical evidence. J. Clin. Psychiatry 1999, 60(Suppl. 10):42-46.
51. Grimm S.W., Richtand N.M., Winter H.R., Stams K.R., Reele S.B. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br. J. Clin. Pharmacol. 2006, 61(1):58-69.
52. Grossman I., Sullivan P.F., Walley N., Liu Y., Dawson J.R., Gumbs C., Gaedigk A., Leeder J.S., McEvoy J.P., Weale M.E., Goldstein D.B. Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet. Med. 2008, 10(10):720-729.
53. Hagg S., Spigset O., Lakso H.A., Dahlqvist R. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6*2001, 57(6-7):493-497.
54. Hamelin B.A., Dorson P.G., Pabis D., Still D., Bouchard R.H., Pourcher E., Rail J., Turgeon J., Crismon M.L. CYP2D6*1057-1063.
55. Hartung B., Wada M., Laux G., Leucht S. Perphenazine for schizophrenia. Cochrane Database Syst. Rev. 2005, (1):CD003443.
56. Hendset M., Hermann M., Lunde H., Refsum H., Molden E. Impact of the CYP2D6*2007, 63(12):1147-1151.
57. Huang M.L., Van Peer A., Woestenborghs R., De Coster R., Heykants J., Jansen A.A., Zylicz Z., Visscher H.W., Jonkman J.H. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin. Pharmacol. Ther. 1993, 54(3):257-268.
58. Iloperidone package insert, 2012. East Hanover, NJ: Novartis Pharmaceuticals Corporation.
59. Inada T., Senoo H., Iijima Y., Yamauchi T., Yagi G. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. Psychiatr. Genet. 2003, 13(3):163-168.
60. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn-Schmiedebergs Arch. Pharmacol. 2004, 369(1):89-104.
61. Jaanson P., Marandi T., Kiivet R.A., Vasar V., Vaan S., Svensson J.O., Dahl M.L. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6*2002, 162(1):67-73.
62. Jerling M., Dahl M.L., Aberg-Wistedt A., Liljenberg B., Landell N.E., Bertilsson L., Sjoqvist F. The CYP2D6*23-428.
63. Jurgens G., Rasmussen H.B., Werge T., Dalhoff K., Nordentoft M., Andersen S.E. Does the medication pattern reflect the CYP2D6*100-105.
64. Kakihara S., Yoshimura R., Shinkai K., Matsumoto C., Goto M., Kaji K., Yamada Y., Ueda N., Ohmori O., Nakamura J. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int. Clin. Psychopharmacol. 2005, 20(2):71-78.
65. Kapitany T., Meszaros K., Lenzinger E., Schindler S.D., Barnas C., Fuchs K., Sieghart W., Aschauer H.N., Kasper S. Genetic polymorphisms for drug metabolism (CYP2D6*101-106.
66. Kassahun K., Mattiuz E., Nyhart E., Obermeyer B., Gillespie T., Murphy A., Goodwin R.M., Tupper D., Callaghan J.T., Lemberger L. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab. Dispos. 1997, 25(1):81-93.
67. Kim E., Yu K.S., Cho J.Y., Shin Y.W., Yoo S.Y., Kim Y.Y., Jang I.J., Shin S.G., Kwon J.S. Effects of DRD2 and CYP2D6*2006, 21(8):519-528.
68. Kohlrausch F.B., Gama C.S., Lobato M.I., Belmonte-de-Abreu P., Callegari-Jacques S.M., Gesteira A., Barros F., Carracedo A., Hutz M.H. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenet. Genomics 2008, 18(7):599-609.
69. Kohnke M.D., Griese E.U., Stosser D., Gaertner I., Barth G. Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry 2002, 35(3):116-118.
70. Kootstra-Ros J.E., Smallegoor W., van der Weide J. The cytochrome P450 CYP1A2*1F and *1D do not affect clozapine clearance in a group of schizophrenic patients. Ann. Clin. Biochem. 2005, 42(Pt 3):216-219.
71. Kubo M., Koue T., Inaba A., Takeda H., Maune H., Fukuda T., Azuma J. Influence of itraconazole co-administration and CYP2D6*2005, 20(1):55-64.
72. Kubo M., Koue T., Maune H., Fukuda T., Azuma J. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6*358-366.
73. Kurose K., Sugiyama E., Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab. Pharmacokinet. 2012, 27(1):9-54.
74. Kwon J.S., Jang J.H., Kang D.H., Yoo S.Y., Kim Y.K., Cho S.J. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. Psychiatry Clin. Neurosci. 2009, 63(1):73-81.
75. Laika B., Leucht S., Heres S., Steimer W. Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6*2009, 9(6):395-403.
76. Laika B., Leucht S., Heres S., Schneider H., Steimer W. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J. 2010, 10(1):20-29.
77. Lam L.C., Garcia-Barcelo M.M., Ungvari G.S., Tang W.K., Lam V.K., Kwong S.L., Lau B.S., Kwong P.P., Waye M.M., Chiu H.F. Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Pharmacopsychiatry 2001, 34(6):238-241.
78. Lamba J.K., Lin Y.S., Schuetz E.G., Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 2012, 54(10):1271-1294.
79. Lane H.Y., Liu Y.C., Huang C.L., Chang Y.C., Wu P.L., Lu C.T., Chang W.H. Risperidone-related weight gain: genetic and nongenetic predictors. J. Clin. Psychopharmacol. 2006, 26(2):128-134.
80. Lee S.J., Bell D.A., Coulter S.J., Ghanayem B., Goldstein J.A. Recombinant CYP3A4*2005, 313(1):302-309.
81. Lett T.A., Wallace T.J., Chowdhury N.I., Tiwari A.K., Kennedy J.L., Muller D.J. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol. Psychiatry 2012, 17(3):242-266.
82. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. Suppl. 1987, 334:1-100.
83. Linnet K., Wiborg O. Influence of CYP2D6*29-634.
84. Linnet K., Wiborg O. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin. Pharmacol. Ther. 1996, 60(1):41-47.
85. Liou Y.J., Wang Y.C., Bai Y.M., Lin C.C., Yu S.C., Liao D.L., Lin M.W., Chen J.Y., Lai I.C. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2004, 49(4):167-173.
86. Llerena A., Alm C., Dahl M.L., Ekqvist B., Bertilsson L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther. Drug Monit. 1992, 14(2):92-97.
87. Llerena A., Dahl M.L., Ekqvist B., Bertilsson L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther. Drug Monit. 1992, 14(3):261-264.
88. Llerena A., Berecz R., Dorado P., de la Rubia A. QTc interval, CYP2D6*2C9 genotypes and risperidone plasma concentrations. J. Psychopharmacol. 2004, 18(2):189-193.
89. Llerena A., de la Rubia A., Berecz R., Dorado P. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6*2C9 genotypes in psychiatric patients. Pharmacopsychiatry 2004, 37(2):69-73.
90. Lohmann P.L., Bagli M., Krauss H., Muller D.J., Schulze T.G., Fangerau H., Ludwig M., Barkow K., Held T., Heun R., Maier W., Rietschel M., Rao M.L. CYP2D6*2003, 36(2):73-78.
91. Lovlie R., Daly A.K., Matre G.E., Molven A., Steen V.M. Polymorphisms in CYP2D6*2001, 11(1):45-55.
92. Luo J.P., Vashishtha S.C., Hawes E.M., McKay G., Midha K.K., Fang J. In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm. Drug Dispos. 2011, 32(7):398-407.
93. Lurasidone package insert, 2012. Marlborough, MA: Sunovion Pharmaceuticals Inc.
94. Mark T.L. For what diagnoses are psychotropic medications being prescribed?: a nationally representative survey of physicians. CNS Drugs 2010, 24(4):319-326.
95. McCullough K.B., Formea C.M., Berg K.D., Burzynski J.A., Cunningham J.L., Ou N.N., Rudis M.I., Stollings J.L., Nicholson W.T. Assessment of the pharmacogenomics educational needs of pharmacists. Am. J. Pharm. Educ. 2011, 75(3):51.
96. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 2006, 163(4):600-610.
97. McGraw J., Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin. Drug Metab. Toxicol. 2012, 8(3):371-382.
98. Megens A.A., Awouters F.H., Schotte A., Meert T.F., Dugovic C., Niemegeers C.J., Leysen J.E. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl) 1994, 114(1):9-23.
99. Melkersson K.I., Scordo M.G., Gunes A., Dahl M.L. Impact of CYP1A2 and CYP2D6*2007, 68(5):697-704.
100. Mendoza R., Wan Y.J., Poland R.E., Smith M., Zheng Y., Berman N., Lin K.M. CYP2D6*2001, 70(6):552-560.
101. Miceli J.J., Anziano R.J., Robarge L., Hansen R.A., Laurent A. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br. J. Clin. Pharmacol. 2000, 49(Suppl. 1):65S-70S.
102. Miceli J.J., Smith M., Robarge L., Morse T., Laurent A. The effects of ketoconazole on ziprasidone pharmacokinetics - a placebo-controlled crossover study in healthy volunteers. Br. J. Clin. Pharmacol. 2000, 49(Suppl. 1):71S-76S.
103. Mihara K., Suzuki A., Kondo T., Yasui N., Furukori H., Nagashima U., Otani K., Kaneko S., Inoue Y. Effects of the CYP2D6*291-294.
104. Mihara K., Kondo T., Yasui-Furukori N., Suzuki A., Ishida M., Ono S., Kubota T., Iga T., Takarada Y., de Vries R., Kaneko S. Effects of various CYP2D6*2003, 25(3):287-293.
105. Miyazaki M., Nakamura K., Fujita Y., Guengerich F.P., Horiuchi R., Yamamoto K. Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone. Drug Metab. Dispos. 2008, 36(11):2287-2291.
106. Mrazek D.A., Lerman C. Facilitating clinical implementation of pharmacogenomics. JAMA 2011, 306(3):304-305.
107. Muller D.J., Brandl E.J., Hwang R., Tiwari A.K., Sturgess J.E., Zai C.C., Lieberman J.A., Kennedy J.L., Richter M.A. The AmpliChip(R) CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6*2012, 16(8):897-903.
108. Nikoloff D., Shim J.C., Fairchild M., Patten N., Fijal B.A., Koch W.H., MacPherson A., Flockhart D., Yoon Y.R., Yoon J.S., Kim Y.H., Shin J.G. Association between CYP2D6*2002, 2(6):400-407.
109. Nozawa M., Ohnuma T., Matsubara Y., Sakai Y., Hatano T., Hanzawa R., Shibata N., Arai H. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther. Drug Monit. 2008, 30(1):35-40.
110. Ohara K., Tanabu S., Yoshida K., Ishibashi K., Ikemoto K., Shibuya H. Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27(6):945-949.
111. Ohmori O., Suzuki T., Kojima H., Shinkai T., Terao T., Mita T., Abe K. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6*107-113.
112. Ohmori O., Kojima H., Shinkai T., Terao T., Suzuki T., Abe K. Genetic association analysis between CYP2D6*2 allele and tardive dyskinesia in schizophrenic patients. Psychiatry Res. 1999, 87(2-3):239-244.
113. Ohnuma T., Shibata N., Matsubara Y., Arai H. Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6*2003, 56(3):315-320.
114. Olanzapine package insert, 2009. Indianapolis, IN: Eli Lilly and Company.
115. Olesen O.V., Linnet K. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br. J. Clin. Pharmacol. 2000, 50(6):563-571.
116. Oosterhuis M., Van De Kraats G., Tenback D. Safety of aripiprazole: high serum levels in a CYP2D6*2007, 164(1):175.
117. Ozdemir V., Kalow W., Tang B.K., Paterson A.D., Walker S.E., Endrenyi L., Kashuba A.D. Evaluation of the genetic component of variability in CYP3A4*2000, 10(5):373-388.
118. Ozdemir V., Bertilsson L., Miura J., Carpenter E., Reist C., Harper P., Widen J., Svensson J.O., Albers L.J., Kennedy J.L., Endrenyi L., Kalow W. CYP2D6*2D6-serotonin-dopamine crosstalk revisited. Pharmacogenet. Genomics 2007, 17(5):339-347.
119. Pan L., Vander Stichele R., Rosseel M.T., Berlo J.A., De Schepper N., Belpaire F.M. Effects of smoking, CYP2D6*21(5):489-497.
120. Panagiotidis G., Arthur H.W., Lindh J.D., Dahl M.L., Sjoqvist F. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6*2007, 29(4):417-422.
121. Park J.Y., Shon J.H., Kim K.A., Jung H.J., Shim J.C., Yoon Y.R., Cha I.J., Shin J.G. Combined effects of itraconazole and CYP2D6*2.
122. Patsopoulos N.A., Ntzani E.E., Zintzaras E., Ioannidis J.P. CYP2D6*2005, 15(3):151-158.
123. Plesnicar B.K., Zalar B., Breskvar K., Dolzan V. The influence of the CYP2D6*2006, 20(6):829-833.
124. Prakash C., Kamel A., Gummerus J., Wilner K. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab. Dispos. 1997, 25(7):863-872.
125. Richelson E., Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000, 68(1):29-39.
126. Riedel M., Schwarz M.J., Strassnig M., Spellmann I., Muller-Arends A., Weber K., Zach J., Muller N., Moller H.J. Risperidone plasma levels, clinical response and side-effects. Eur. Arch. Psychiatry Clin. Neurosci. 2005, 255(4):261-268.
127. Roh H.K., Chung J.Y., Oh D.Y., Park C.S., Svensson J.O., Dahl M.L., Bertilsson L. Plasma concentrations of haloperidol are related to CYP2D6*2001, 52(3):265-271.
128. Rostami-Hodjegan A., Amin A.M., Spencer E.P., Lennard M.S., Tucker G.T., Flanagan R.J. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J. Clin. Psychopharmacol. 2004, 24(1):70-78.
129. Sajjad S.H. CYP2D6 genotype and tardive dyskinesia. Br. J. Psychiatry 1997, 170:580.
130. Saphris package insert Whitehouse Station 2013, NJ: Merck & Co., Inc.
131. Schnoll R.A., Shields A.E. Physician barriers to incorporating pharmacogenetic treatment strategies for nicotine dependence into clinical practice. Clin. Pharmacol. Ther. 2011, 89(3):345-347.
132. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996, 124(1-2):57-73.
133. Scordo M.G., Spina E., Facciola G., Avenoso A., Johansson I., Dahl M.L. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 1999, 147(3):300-305.
134. Scordo M.G., Spina E., Romeo P., Dahl M.L., Bertilsson L., Johansson I., Sjoqvist F. CYP2D6*10):679-683.
135. Sheehan J.J., Sliwa J.K., Amatniek J.C., Grinspan A., Canuso C.M. Atypical antipsychotic metabolism and excretion. Curr. Drug Metab. 2010, 11(6):516-525.
136. Sheffield L.J., Phillimore H.E. Clinical use of pharmacogenomic tests in 2009. Clin. Biochem. Rev. 2009, 30(2):55-65.
137. Shi Y., Li Y., Tang J., Zhang J., Zou Y., Cai B., Wang L. Influence of CYP3A4*226-231.
138. Shimoda K., Morita S., Yokono A., Someya T., Hirokane G., Sunahara N., Takahashi S. CYP2D6*2000, 22(4):392-396.
139. Sistonen J., Fuselli S., Palo J.U., Chauhan N., Padh H., Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6*2009, 19(2):170-179.
140. Someya T., Shimoda K., Suzuki Y., Sato S., Kawashima Y., Hirokane G., Morita S., Yokono A., Takahashi S. Effect of CYP2D6*2003, 28(8):1501-1505.
141. Spyker D.A., Munzar P., Cassella J.V. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J. Clin. Pharmacol. 2010, 50(2):169-179.
142. Stephan P.L., Jaquenoud Sirot E., Mueller B., Eap C.B., Baumann P. Adverse drug reactions following nonresponse in a depressed patient with CYP2D6*2006, 39(4):150-152.
143. Stroup T.S. Heterogeneity of treatment effects in schizophrenia. Am. J. Med. 2007, 120(4 Suppl. 1):S26-S31.
144. Sunwoo Y.E., Ryu J., Jung H., Kang W., Liu K., Yoon Y., Lee S., Shin J. Disposition of chlorpromazine in Korean healthy subjects with CYP2D6*2004, 75(2):P9. [Abstract].
145. Suzuki A., Otani K., Mihara K., Yasui N., Kaneko S., Inoue Y., Hayashi K. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 1997, 7(5):415-418.
146. Suzuki T., Mihara K., Nakamura A., Nagai G., Kagawa S., Nemoto K., Ohta I., Arakaki H., Uno T., Kondo T. Effects of the CYP2D6*2011, 33(1):21-24.
147. Swen J.J., Nijenhuis M., de Boer A., Grandia L., Maitland-van der Zee A.H., Mulder H., Rongen G.A., van Schaik R.H., Schalekamp T., Touw D.J., van der Weide J., Wilffert B., Deneer V.H., Guchelaar H.J. Pharmacogenetics: from bench to byte - an update of guidelines. Clin. Pharmacol. Ther. 2011, 89(5):662-673.
148. Teutsch S.M., Bradley L.A., Palomaki G.E., Haddow J.E., Piper M., Calonge N., Dotson W.D., Douglas M.P., Berg A.O. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet. Med. 2009, 11(1):3-14.
149. Thanacoody R.H., Daly A.K., Reilly J.G., Ferrier I.N., Thomas S.H. Factors affecting drug concentrations and QT interval during thioridazine therapy. Clin. Pharmacol. Ther. 2007, 82(5):555-565.
150. Thomas P., Srivastava V., Singh A., Mathur P., Nimgaonkar V.L., Lerer B., Thelma B.K., Deshpande S.N. Correlates of response to Olanzapine in a North Indian Schizophrenia sample. Psychiatry Res. 2008, 161(3):275-283.
151. Tiwari A.K., Deshpande S.N., Rao A.R., Bhatia T., Lerer B., Nimgaonkar V.L., Thelma B.K. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4*2005, 75(1):21-26.
152. US Food and Drug Administration Drug Approval Package. Iloperidone 2009, (Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022192s000TOC.cfm. Accessed August 11, 2012).
153. US Food and Drug Administration Table of Pharmacogeneomic Biomarkers in Drug Labels Available at:, (Accessed July 9, 2012). http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm
154. van der Weide J., van Baalen-Benedek E.H., Kootstra-Ros J.E. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther. Drug Monit. 2005, 27(4):478-483.
155. Vogel F. Moderne probleme der humangenetik. [German]. Ergeb. Inn. Med. Kinderheilkd 1959, 12:52-125.
156. von Bahr C., Movin G., Nordin C., Liden A., Hammarlund-Udenaes M., Hedberg A., Ring H., Sjoqvist F. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin. Pharmacol. Ther. 1991, 49(3):234-240.
157. Westlind-Johnsson A., Hermann R., Huennemeyer A., Hauns B., Lahu G., Nassr N., Zech K., Ingelman-Sundberg M., von Richter O. Identification and characterization of CYP3A4*20, a novel rare CYP3A4*2006, 79(4):339-349.
158. Williams J.A., Ring B.J., Cantrell V.E., Jones D.R., Eckstein J., Ruterbories K., Hamman M.A., Hall S.D., Wrighton S.A. Comparative metabolic capabilities of CYP3A4*2002, 30(8):883-891.
159. Winter H.R., Earley W.R., Hamer-Maansson J.E., Davis P.C., Smith M.A. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J. Child Adolesc. Psychopharmacol. 2008, 18(1):81-98.
160. Wojcikowski J., Maurel P., Daniel W.A. Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. Drug Metab. Dispos. 2006, 34(3):471-476.
161. Yasui-Furukori N., Kondo T., Suzuki A., Mihara K., Tokinaga N., Inoue Y., Otani K., Kaneko S. Effect of the CYP2D6*2001, 52(1-2):139-142.
162. Yoshii K., Kobayashi K., Tsumuji M., Tani M., Shimada N., Chiba K. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci. 2000, 67(2):175-184.
163. Young D., Midha K.K., Fossler M.J., Hawes E.M., Hubbard J.W., McKay G., Korchinski E.D. Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6. Eur. J. Clin. Pharmacol. 1993, 44(5):433-438.
164. Zahari Z., Salleh M.R., Teh L.K., Ismail R. Influence of CYP2D6*2009, 16(3):12-20.
165. Zanger U.M., Turpeinen M., Klein K., Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 2008, 392(6):1093-1108.
166. Zhang J.P., Malhotra A.K. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin. Drug Metab. Toxicol. 2011, 7(1):9-37.
167. Zhou S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin. Pharmacokinet. 2009, 48(12):761-804.
168. Zink M., Englisch S., Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr. Opin. Psychiatry 2010, 23(2):103-111.
169. Ziprasidone package insert, 2012. New York, NY: Pfizer Inc.
170. Zochowska D., Wyzgal J., Paczek L. Impact of CYP3A4*17(3):36-44.